# Fundamental limits of repeaterless quantum communications

Article · Stefano Pirandola, Riccardo Laurenza, Carlo Ottaviani, Leonardo Banchi

- Archive id: arxiv:1510.08863
- Published: 2017-04-26
- Venue: Nature Communications
- DOI: https://doi.org/10.1038/ncomms15043
- arXiv: https://arxiv.org/abs/1510.08863
- PMID: 28443624
- Citations: 1,395
- Source URL: https://doi.org/10.1038/ncomms15043
- PDF: https://www.nature.com/articles/ncomms15043.pdf
- Provenance: openalex+arxiv

## Abstract

Quantum communications promises reliable transmission of quantum information, efficient distribution of entanglement and generation of completely secure keys. For all these tasks, we need to determine the optimal point-to-point rates that are achievable by two remote parties at the ends of a quantum channel, without restrictions on their local operations and classical communication, which can be unlimited and two-way. These two-way assisted capacities represent the ultimate rates that are reachable without quantum repeaters. By constructing an upperbound based on the relative entropy of entanglement and devising a dimension-independent technique dubbed "teleportation stretching", we establish these capacities for many fundamental channels, namely bosonic lossy channels, quantum-limited amplifiers, dephasing and erasure channels in arbitrary dimension. In particular, we determine the fundamental rate-loss trade-off affecting any protocol of quantum key distribution. Our findings set the ultimate limits of point-to-point quantum communications and provide the most precise and general benchmarks for quantum repeaters.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Quantum Networks & Post-Quantum Cryptography](https://space-kitty.com/topics/quantum-communication-crypto)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.